Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations

British Journal of Haematology

Volumn 153, Issue 1, 2011, Pages 33-42

  Riccioni, Roberta ^a   Pelosi, Elvira ^a   Riti, Viviana ^a   Castelli, Germana ^a   Lo Coco, Francesco ^b   Testa, Ugo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Acute myeloid leukaemia; FMS related tyrosine kinase 3 mutations; Immunophenotype; Trail; Vascular endothelial growth factor receptor

Indexed keywords

ASPARTIC ACID; CD123 ANTIGEN; CD135 ANTIGEN; CD34 ANTIGEN; FLT3 LIGAND; GROWTH FACTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CANCER PATIENT; CELL COUNT; CELL STIMULATION; CONTROLLED STUDY; FMS RELATED TYROSINE KINASE 3 GENE; GENE; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MONOCYTE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TANDEM REPEAT; WILD TYPE;

ANTIGENS, CD34; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; MONOCYTES; MUTATION; RECEPTOR, TIE-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79952590045     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08577.x     Document Type: Article

References (42)

1. Al-Kali, A., Jones, D., Cortes, J., Faderl, S., Xue, A. & Garcia-Manero, G. (2009) Patterns of molecular response to and relapse after combination of Sorafenib, Idarubicin, and Cytarabine in patients with newly diagnosed FLT3-mutant acute myeloid leukemia (AML). Blood, 114, abstract No. 2079.
2. Armstrong, S.A., Kung, A.L., Mabon, M.E., Silverman, L.B., Stam, R.W., Den Boer, M.L., Pleters, R., Kersey, J.H., Sallan, S.E., Fletcher, J.A., Golub, T.R., Griffin, J.D. & Korsmeyer, S.J. (2003) Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell, 3, 173-183.
3. Auclair, D., Miller, D., Yatsula, V., Pickett, W., Carter, C., Chang, Y., Zhang, X., Wilkie, D., Burd, A., Shi, H., Rocks, S., Gedrich, R., Abriola, L., Vasavada, H., Lynch, M., Dumas, J., Trail, P.A. & Wilhelm, S.M. (2007) Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia, 21, 439-445.
4. Bacher, U., Haferlach, C. & Kern, W. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood, 111, 2527-2537.
5. Boiers, C., Buza-Vidas, N., Jensen, C.T., Pronk, C., Kharazi, S., Wittmann, L., Sitnicka, E., Hulquist, A. & Jacobsen, S.E. (2010) Expression and role of FLT3 in regulation of the earliest stage of normal granulocyte-monocyte progenitor development. Blood, 115, 5061-5068.
6. Chen, J., Odenike, O. & Rowley, J. (2010) Leukaemogenesis: more than mutant genes. Nature Reviews Cancer, 10, 23-36.
7. Chomczynski, P. & Sacchi, N. (1987) Single-step method of RNA isolation by acid guanudinium thiocyanate-phenol-chloform extraction. Analytical Biochemistry, 162, 156-159.
8. Estey, E. & Dohner, H. (2006) Acute myeloid leukemia. Lancet, 368, 1894-1907.
9. Fitzgibbon, J., Smith, L.L., Raghavan, M., Smith, M.L., Debernardi, S., Skoulakis, S., Lillington, D., Lister, T.A. & Young, B.D. (2005) Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Research, 15, 65 9152-9154.
10. Gabbianelli, M., Pelosi, E., Montesoro, E., Valtieri, M., Luchetti, L., Samoggia, P., Vitelli, L., Barberi, T., Testa, U., Lyman, S. & Peschle, C. (1995) Multi-level effect of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progentors/monocytic precursors. Blood, 86, 1661-1670.
11. Gale, R.E., Green, C., Allen, C., Mead, A.J., Burnett, A.K., Hills, R.K., Linch, D.C. & Medical Research Council Adult Working Party. (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 111, 2776-2784.
12. Jin, L., Lee, E.M., Ramshaw, H.S., Busfield, S.J., Peoppl, A.G., Wilkinson, L., Guthridge, M.A., Thomas, D., Barry, E.F., Boyd, A., Gearing, D.P., Vairo, G., Lopez, A.F., Dick, J.E. & Lock, R.B. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5, 31-42.
13. Kang, H.J., Lee, J.W., Kho, S.H., Kim, M.J., Seo, Y.J., Kim, H., Shin, H.Y. & Ahn, H.S. (2010) High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia. Journal of Korean Medical Science, 25, 841-845.
14. Kelly, L.M., Liu, Q., Kutck, J.L., Williams, I.R., Boulton, C.L. & Gilliland, D.G. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310-318.
15. Kuchenbauer, F., Kern, W., Schoch, C., Kohlmann, A., Hiddemann, W., Haferlach, T. & Schnittger, S. (2005) Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica, 90, 1617-1625.
16. Lange, B., Valtieri, M., Santoli, D., Caracciolo, D., Mavilio, F., Gemperlein, I., Griffin, C., Emanuel, B., Finan, J., Nowell, P. & Rovera, G. (1987) Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood, 7, 192-199.
17. Mackarehtschian, K., Hardin, J.D., Moore, K.A., Boast, S., Goff, S.P. & Lemischka, I.R. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity, 3, 147-161.
18. Mathews, W., Jordan, C.T., Wiegand, G.W., Pardoll, D. & Lemischka, I.R. (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell, 45, 1143-1152.
19. McKenna, H.J., Stocking, K.L., Miller, R.E., Brasel, K., De Smedt, T., Maraskovsky, E., Maliszewski, C.R., Lynch, D.H., Smith, J., Pulendran, B., Roux, R., Teepe, M., Lyman, S.D. & Peschon, J. (2000) Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood, 95, 3489-3497.
20. Mead, A.J., Linch, D.C. & Hills, R.K. (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 tandem duplications in patients with acute myeloid leukemia. Blood, 110, 1262-1270.
21. Metzelder, S., Scholl, S., Matthias, K., Reiter, A., Meyer, R.G. & Heinicke, T. (2009) Compassionate use of sorafenib in relapsed and refractory Flt3-ITD positive acute myeloid leukemia. Blood, 114, abstract No. 2060.
22. Mrozek, K., Marcucci, G., Paschka, P., Whitman, S.P. & Bloomfield, C.D. (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, 109, 431-448.
23. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horrike, S. & Kashima, K. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911-1918.
24. Ozeki, K., Kiyoi, H., Hirose, Y., Iwai, M., Ninomiya, M., Kodera, Y., Miyawaki Kuriyama, S.K., Shimazaki, C., Akiyama, H., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Ueda, R., Ohno, R., Emi, N. & Naoe, T. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood, 103, 1901-1908.
25. Pemmaraju, N., Kantarjian, H.M., Ravandi, F., Garcia-Manero, G., Gautam, B. & Parikh, S.A. (2009) FLT3 inhibitor therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): impact on survival according to FLT3 status. Blood, 114, abstract No. 1026.
26. Riccioni, R., Rossini, A., Calbrò, L., Diverio, D., Pasquini, L., Lo-Coco, F., Peschle, C. & Testa, U. (2004) Immunophenotypic features of acute myeloid leukemia overexpressing the interleukin 3 receptor alpha chain. Leukaemia & Lymphoma, 45, 1511-1517.
27. Riccioni, R., Pasquini, L., Mariani, G., Saulle, E., Rossini, A., Diverio, D., Pelosi, E., Vitale, A., Chierichini, A., Cedrone, M., Foà, R., LoCoco, F., Peschle, C. & Testa, U. (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica, 90, 612-624.
28. Riccioni, R., Diverio, D., Mariani, G., Buffolino, S., Riti, V., Saulle, E., Petrucci, E., Cedrone, M., Lo-Coco, F., Foà, R., Peschle, C. & Testa, U. (2007) Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts. Stem Cells, 25, 1862-1871.
29. Riccioni, R., Diverio, D., Riti, V., Buffolino, S., Mariani, G., Boe, A., Cedrone, M., Ottone, T., Foà, R. & Testa, U. (2009) Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemia with mutated FMS-related tyrosine kinase 3 receptor. British Journal of Haematology, 14, 376-387.
30. Scholl, C., Gilliland, D.G. & Frohling, S. (2008) Deregulation of signaling pathways in acute myeloid leukemia. Seminars in Oncology, 35, 336-345.
31. Schroeder, T., Saure, C., Bruns, I., Zohren, F., Czibere, A.G. & Safaian, N.N. (2009) Clinical efficacy of sorafenib in patients with acute myeloid leukemia (AML) and activating FLT3-mutations. Blood, 114, abstract No. 2057.
32. Sitnicka, E., Bryder, D., Theilgaard-Monch, K., Buza-Vidas, N., Adolfsson, J. & Jacobsen, S.E. (2002) Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. Immunity, 17, 463-472.
33. Sitnicka, E., Buza-Vidas, N., Ahlenius, H., Ciliop, C.M., Gekas, C., Nygren, J.M., Mansson, R., Cheng, M., Jensen, C.T., Swensson, M., Leandersson, K., Agace, W.W., Sigvardsson, M. & Jacobsen, S.E. (2007) Critical role of FLT3 ligand in IL-7 receptor independent T lymphopoiesis and regulation of lymphoid-primed multipotent progenitors. Blood, 110, 2955-2964.
34. Testa, U., Riccioni, R., Militi, S., Coccia, E., Stellacci, E., Samoggia, P., Latagliata, R., Mariani, G., Rossini, A., Battistini, A., Lo-Coco, F. & Peschle, C. (2002) Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhnaced blast proliferation, increased cellularity, and poor prognosis. Blood, 100, 2980-2988.
35. Testa, U., Riccioni, R., Biffoni, M., Diverio, D., Lo-Coco, F., Foà, R., Peschle, C. & Frankel, A.E. (2005) Diphteria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood, 106, 2527-2529.
36. Thiede, C., Steudel, C. & Mohr, B. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
37. Torres, L.A., Barbarroja, N., Dorado, G., Velasco, F. & Lopez-Pedrera, C. (2009) VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications. British Journal of Haematology, 145, 836-844.
38. Van Dogen, J.J., MacIntyre, E.A., Gabert, J.A., Delabesse, E., Rossi, V., Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., Parreira, A., Gameiro, P., Diaz, M.G., Malec, M., Lagerak, A.W., San Miguel, J.F. & Biondi, A. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia, 13, 1901-1928.
39. Whitman, S.P., Archer, K.J., Feng Baldus, L.C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Variman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. & Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233-7239.
40. Whitman, S.P., Ruppert, A.S. & Radmacher, M.D. (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood, 111, 1552-1559.
41. Yamamoto, Y., Kiyoi, H., Nakano, Y., Sukuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimaaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. & Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 2434-2439.
42. Zhang, W., Konopleva, M., Shi, Y.X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintàs-Cardama, A., Small, D., Cortes, J. & Andreef, M. (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Journal of the National Cancer Institute, 100, 184-198.